http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1578764-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45a3703d03a4b21be619937f5ad63b8b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate | 2003-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dffa69e923a88855a242377da44f8e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5045979a537ed4f18361d19d452fe590 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f9f9e140afbffe9ed6c88947b1b4b4d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2298a73a486d77548ddeb2c07c5cbce8 |
| publicationDate | 2005-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1578764-A2 |
| titleOfInvention | Thymidylate synthase polymorphisms for use in screening for cancer susceptibility |
| abstract | The present invention discloses a novel single nucleotide polymorphism (SNP) in the isolated 5' tandem repeats of the thymidylate synthase (TS) gene and methods for its use. The novel SNP, located in the 12th nucleotide of a 28 bp third tandem repeat (3R) of the TS gene, substitutes a C for a G, and is the variant form of the repeat. Subjects with the wild-type form of 3R have greater transcription of the TS gene than subjects with the variant form. The invention also reveals that a six base pair deletion in the 3' region of TS (-6 bp/1494) indicates mRNA instability and thus reduced production of TS. In diseased tissue, such as cancer, reduced production of TS is beneficial because it prevents the cancerous cells from growing and spreading. Analysis of either polymorphism or both together allows for prediction of a subject's response to chemotherapeutic and anti-cardiovascular disease treatments because both diseases are related to TS levels in a subject. |
| priorityDate | 2002-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1265.